KEYNOTE-671 Investigators. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with …
この記事を読む
一臨床医の勉強のための備忘録です。間違いなどあればご指摘を頂ければ幸いです。
この記事を読む
KEYNOTE-671 Investigators. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with …
この記事を読む
Real-world outcomes of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC)treated with osimertinib (osi…
この記事を読む
Neoadjuvant Osimertinib for the Treatment of Stage I-ⅢA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Can…
この記事を読む
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous …
この記事を読む
PhaseⅢ KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistan…
この記事を読む
A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE III…
この記事を読む
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. Cho BC et al.N Engl J Med. 2024 Jun 26.…
この記事を読む
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following pro…
この記事を読む
Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted …
この記事を読む
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomi…